Abera Bioscience (ABERA) Q2 2025 earnings summary

Executive summary

• Focused efforts in spring and summer laid the foundation for the next development phase, including securing financing for the first clinical study of the pneumococcal vaccine candidate Ab-01.12.

• Positive preclinical results for both influenza and pneumococcal vaccine candidates, with regulatory support to proceed to human studies.

• Strategic collaborations intensified, and new funding from CEPI and a fully subscribed directed share issue strengthen the financial position.

Financial highlights

• Q2 2025 revenue was 4,297 KSEK, mainly from grants and currency gains, compared to 4,506 KSEK in Q2 2024.

• Operating costs for the quarter were -5,140 KSEK, with a net result of -833 KSEK (vs. -665 KSEK in Q2 2024).

• Cash and bank balances at June 30, 2025, were 7,948 KSEK, up from 2,628 KSEK a year earlier.

• Equity at period end was 7,768 KSEK, with a solidity of 56%.

• Cash flow from operations was 2,574 KSEK, a significant improvement from -3,739 KSEK in Q2 2024.

Outlook and guidance

• Preparations for the first clinical study of Ab-01.12 are intensifying, with the goal to start and complete the phase I trial in 2026.

• Additional CEPI funding will support further development and optimization of the influenza vaccine platform.

• Ongoing grants from UK Vaccine Network and CEPI secure funding for research staff through March 2026.